{
    "clinical_study": {
        "@rank": "97622", 
        "acronym": "HMPL", 
        "arm_group": {
            "arm_group_label": "Sulfatinib capsule", 
            "arm_group_type": "Experimental", 
            "description": "cohort 1: Sulfatinib single oral dosing;after 7days,Sulfatinib continuous oral dosing ( once a day)  28days as a cycle."
        }, 
        "brief_summary": {
            "textblock": "Sulfatinib (HMPL-012) is a novel oral small molecule that selectively inhibits vascular\n      endothelial growth factor receptors (VEGFR) 1, 2, and 3 and inhibits FGFR kinase activity\n      has demonstrated potent inhibitory effects on multiple human tumor xenografts. This\n      first-in-human study is conducted to assess the maximum tolerated dose (MTD) and recommended\n      dose for phase II ,to evaluate the pharmacokinetics , safety and preliminary anti-tumor\n      activity of HMPL-012 at single doses and multiple doses ."
        }, 
        "brief_title": "Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Tumor", 
        "detailed_description": {
            "textblock": "This will be an open-label, phase I study. This study will evaluate the safety and\n      pharmacokinetics of HMPL-012 after a single administration followed by a 28-Day continuous\n      course of therapy; evaluate the safety and preliminary efficacy in an open-label\n      administration of at the MTD. All subjects of this study will be permitted to continue\n      therapy with only safety monitoring and monthly assessments for progression, if the product\n      is well tolerated and the subject has stable disease or better"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        \u2022\u2265 18 and \u2264 70 years of age\n\n          -  Histological or cytological confirmed solid malignant tumor\n\n          -  ECOG performance status of 0-2\n\n          -  Standard regimen failed or no standard regimen available\n\n          -  Life expectancy of more than 12 weeks\n\n          -  LVEF \u2265 50%\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women\n\n          -  Adequate hepatic, renal, heart, and hematologic functions (platelets <75 \u00d7 109/L,\n             neutrophil <1.5 \u00d7 109/L, hemoglobin < 90g/dl ,serum creatinine within upper limit of\n             normal(ULN), total bilirubin and serum transaminase within upper limit of\n             normal(ULN), and PT, APTT, TT, Fbg normal\n\n          -  Any factors that influence the usage of oral administration\n\n          -  Evidence of uncontrolled CNS metastasis\n\n          -  Intercurrence with one of the following: non-controlled hypertension, coronary artery\n             disease, arrhythmia and heart failure\n\n          -  Abuse of alcohol or drugs\n\n          -  Less than 4 weeks from the last clinical trial\n\n          -  Previous treatment with VEGF/VEGFR inhibition\n\n          -  Disability of serious uncontrolled intercurrence infection\n\n          -  Uncontrolled hemorrhage in GI\n\n          -  Within 12 months before the first treatment occurs artery/venous thromboembolic\n             events, such as cerebral vascular accident (including transient ischemic attack) etc.\n\n          -  Within 6 months before the first treatment occurs acute myocardial infarction, acute\n             coronary syndrome or CABG\n\n          -  Bone fracture or wounds that was not cured for a long time\n\n          -  Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133157", 
            "org_study_id": "2009-012-00CH1"
        }, 
        "intervention": {
            "arm_group_label": "Sulfatinib capsule", 
            "description": "Sulfatinib  is a capsule in the form of25, 50mg , 100mg; oral, once a day", 
            "intervention_name": "Sulfatinib", 
            "intervention_type": "Drug", 
            "other_name": "HMPL-012"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "tumor", 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "contact": {
                "email": "huam@hmpglobal.com", 
                "last_name": "Hua Mu, PHD", 
                "phone": "021-50790088"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100071"
                }, 
                "name": "Academy of Military Medical Affiliated Hopital"
            }, 
            "investigator": {
                "last_name": "ming j xu, phd", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Study of Safety and Pharmacokinetics of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors", 
        "other_outcome": {
            "description": "Anti-tumoral efficacy will be assessed by best radiographic response based on Response Evaluation Criteria in Solid Tumors (RECIST v 1.0) at baseline (Day -14 to -1) and at the end of two 28-Day cycles of therapy . For patients that continue on repeat 28-Day cycles after the primary evaluation period, progression will be assessed after each two 28-Day cycles of therapy.", 
            "measure": "Objective Response Rate", 
            "safety_issue": "No", 
            "time_frame": "every 4 weeks until 1 year"
        }, 
        "overall_contact": {
            "email": "huam@hmplglobal.com", 
            "last_name": "Hua Mu, PH.D", 
            "phone": "86-21-50790088"
        }, 
        "overall_official": {
            "affiliation": "Academy of Military Medical  Affiliated Hopital", 
            "last_name": "Ming J Xu, PHD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is evaluation of safety during the first 28-day cycle 1 of therapy following the initiation of multiple dosing of HMPL-012. The safety variables to be evaluated in this study are adverse events, physical examinations, vital signs (specifically including blood pressure), clinical laboratory evaluations including serum chemistry, hematology , and urinalysis (with detailed sediment analysis, proteinuria, and 24-hour urine for collection for protein), and electrocardiograms (ECGs) in triplicate", 
            "measure": "To assess number of participants with adverse events as a measure of safety and tolerability during dose escalating", 
            "safety_issue": "Yes", 
            "time_frame": "1-28days after every drug administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133157"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "In the study of single-dose, full PK profiles of HMPL-012 will be obtained following administration of a single oral dose of HMPL-012 on Day 1 to Day 3. At multiple-dose, PK sampling will include a pre-dose and at the 1,4,8,12 hour time points on days 1,14,28 of dosing in the first 28-Day cycle of therapy, and pre-dose on days 2, 3, 7, 15 and 29 of the first 28-Day cycle of therapy and pre-dose on days 56 of the cycle 2.", 
            "measure": "To measure the plasma concentration of HMPL-012 in single and repeated doses", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1-3 Single Dose and Day 1-56 Steady State"
        }, 
        "source": "Hutchison Medipharma Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hutchison Medipharma Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}